Skip to main content

Cancer

Cancer Research Institute

Clinical Trials

Showing 37-45 out of 134 results.
NCT04586231

An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Icon for trial | MK-6482-011 An Open-label, Randomized, Phase 2 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L

This study is currently enrolling.

This trial is being done to test MK-6482 + lenvatinib in people with a type of kidney cancer called advanced clear cell Renal Cell Carcinoma (ccRCC). MK-6482 is still being researched and has not been approved to use alone or w ...

NCT05948865

CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Advanced or Metastatic Solid Tumors

Icon for trial | CPO301-US-101 CPO301-US-101: A Phase 1, Multicenter, Single Agent Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of CPO301, an EGFR-Targeting Antibody-Drug Conjugate, in Adult Patients with Adv

This study is currently enrolling.

The purpose of the study, called CPO301-US-101, is to see if CPO301 (also known as SYS6010) is safe and effective in treating your type of cancer when administered as an intravenous (administered into the vein) infusion (IV) ov ...